Decheng Capital — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
BiotechFremont, US
Feng Wang-Johanning(Executive Officer, Director)Gary Johanning(Executive Officer)
BoardPeter Colabuono(Director)in
Board seatXiangmin Cui· per SEC Form D · $6M raise · filed Jan 2023
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)Robert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)Matthew Patterson(Director)Scott Biller(Director)
Co-investorsAtlas VentureForesite CapitalThe Column GroupARCH Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.